A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel

NCT00764166 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

254

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Prostate

Interventions

DRUG: Docetaxel + hormonal treatment (LH-RH agonist)
DRUG: Hormonal treatment (LH-RH agonist)

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]